Priovant Therapeutics is focused on developing targeted therapies for severe autoimmune diseases, with its lead molecule, brepocitinib, being a notable innovation. Brepocitinib is an oral, once-daily dual inhibitor of TYK2 and JAK1, designed to selectively suppress the signaling of various cytokines associated with autoimmunity, including type I and type II interferons, IL-6, IL-12, and IL-23. This dual inhibition is particularly advantageous for treating conditions with complex pathobiologies, as it addresses the underlying dysregulation of cytokines that contribute to autoimmune responses. The molecule has shown promising results in seven Phase 2 studies, demonstrating clinically meaningful efficacy and a safety profile comparable to existing JAK inhibitors. Currently, Priovant is advancing brepocitinib through multiple Phase 3 trials, including the VALOR Study for dermatomyositis and the CLARITY Study for non-infectious uveitis.

The company is addressing significant unmet needs in the treatment of autoimmune diseases, particularly in conditions like dermatomyositis and non-infectious uveitis, where existing therapies are often inadequate or associated with serious safety risks. Dermatomyositis, characterized by muscle weakness and skin rashes, has limited treatment options, and brepocitinib's dual inhibition may offer enhanced efficacy compared to current therapies. Similarly, non-infectious uveitis, a leading cause of blindness, has few effective treatments, and brepocitinib has shown promising results in clinical trials, including the potential to prevent vision-threatening complications like macular edema. Through its innovative approach, Priovant aims to provide more effective and convenient treatment options for patients suffering from these challenging autoimmune conditions.

United States

Priovant Therapeutics is a clinical-stage biotechnology company focused on delivering novel therapies for autoimmune diseases with the greatest morbidity and mortality. We are developing oral brepocitinib, a potential first-in-class dual inhibitor of TYK2 and JAK1, across multiple severe autoimmune indications, unlocking new treatment options for patients who are underserved by existing therapies.

Priovant Therapeutics

Company Details